---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-004559"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:20:26.008862+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Axsome announces preliminary FY2024 revenue $385.2M; Auvelity $291.4M

## Summary
- Total product revenue Q4 $118.3M, full year $385.2M (unaudited preliminary).
- Auvelity net product sales Q4 $92.6M, full year $291.4M.
- Sunosi net product revenue Q4 $25.7M, full year $93.8M.
- CEO cites positive Phase 3 results for AXS-05 (Alzheimer's agitation) and AXS-12 (narcolepsy); regulatory filings planned in 2025.
- Active launch preparations underway for AXS-07 (migraine), if approved.

## SEC filing metadata
- accession: 0000950170-25-004559
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000095017025004559/0000950170-25-004559-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000095017025004559/axsm-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-004559
- JSON: https://secwatch.observer/filing/0000950170-25-004559.json
- Plain text: https://secwatch.observer/filing/0000950170-25-004559.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.